We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
- Authors
Pfisterer, Jacobus; Plante, Marie; Vergote, Ignace; du Bois, Andreas; Hirte, Hal; Lacave, Angel J; Wagner, Uwe; Stähle, Anne; Stuart, Gavin; Kimmig, Rainer; Olbricht, Sigrid; Le, Tien; Emerich, Janusz; Kuhn, Walther; Bentley, James; Jackisch, Christian; Lück, Hans-Joachim; Rochon, Justine; Zimmermann, Annamaria Hayden; Eisenhauer, Elizabeth; AGO-OVAR; NCIC CTG; EORTC GCG
- Abstract
Most patients with advanced ovarian cancer develop recurrent disease. For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel; however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation. Thus, an alternative regimen without significant neurotoxicity was evaluated by comparing gemcitabine plus carboplatin with single-agent carboplatin in platinum-sensitive recurrent ovarian cancer patients.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Vol 24, Issue 29, p4699
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.06.0913